Dlin-MC3-DMA: Ionizable Lipid for Potent siRNA & mRNA Nanoparticle Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid essential for lipid nanoparticle (LNP)-mediated siRNA and mRNA drug delivery (Wang et al., 2022). It achieves up to 1000-fold improved hepatic gene silencing compared to its precursor DLin-DMA under matched in vivo conditions (source). This lipid is positively charged at acidic pH, enabling endosomal escape, but remains neutral at physiological pH, minimizing cytotoxicity. Dlin-MC3-DMA is a benchmark standard for mRNA vaccine LNP design and is extensively validated by machine learning and experimental studies (Wang et al., 2022). Product-grade Dlin-MC3-DMA (SKU A8791) is supplied by APExBIO (product page).

Biological Rationale

Lipid nanoparticles (LNPs) are the leading non-viral vectors for nucleic acid therapeutics. Ionizable cationic lipids like Dlin-MC3-DMA are essential for LNP-based delivery of siRNA and mRNA. Their structure enables nucleic acid binding, protection from degradation, and efficient cell uptake (Wang et al., 2022). Dlin-MC3-DMA's unique pH-dependent ionization facilitates cytosolic release of payloads after endocytosis, critical for therapeutic gene silencing or protein expression. Its integration into LNPs with DSPC, cholesterol, and PEG-lipids is standard in clinical mRNA vaccine and siRNA drug development (see prior review—this article provides updated mechanistic and benchmarking data).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is an ionizable cationic lipid. At acidic pH (e.g., within endosomes, pH ~5.5), its tertiary amine is protonated, imparting a positive charge (Wang et al., 2022). This charge enables strong electrostatic interactions with the anionic endosomal membrane, destabilizing it and promoting endosomal escape of the LNP's nucleic acid payload. At physiological pH (~7.4), the lipid is largely neutral, reducing systemic toxicity and off-target effects. Dlin-MC3-DMA is formulated with helper lipids such as DSPC and cholesterol for membrane structure and stability, and PEG-lipids for colloidal stability and pharmacokinetics. This combination enables efficient delivery, endosomal escape, and cytoplasmic release of siRNA or mRNA (see mechanistic comparison; this article offers direct quantitative evidence and design guidance).

Evidence & Benchmarks

• Dlin-MC3-DMA enables ~1000-fold greater hepatic gene silencing potency versus DLin-DMA in mouse models, with an ED50 of 0.005 mg/kg for TTR knockdown (Wang et al., 2022).
• In non-human primates, Dlin-MC3-DMA LNPs achieve potent TTR silencing at an ED50 of 0.03 mg/kg, outperforming alternative ionizable lipids under matched conditions (Wang et al., 2022).
• Machine learning models (LightGBM) predict and validate Dlin-MC3-DMA as a top-performing ionizable lipid for mRNA vaccine LNPs, with R2 > 0.87 for IgG titer prediction in murine studies (Wang et al., 2022, Table S3).
• Molecular dynamics simulations confirm efficient mRNA encapsulation and molecular aggregation behavior of Dlin-MC3-DMA LNPs, supporting observed experimental potency (Wang et al., 2022, Fig. 5).
• Dlin-MC3-DMA LNPs show superior endosomal escape compared to SM-102 and other lipids, as measured by in vitro and in vivo transfection efficiency (Wang et al., 2022).

Applications, Limits & Misconceptions

Applications:

• Lipid nanoparticle-mediated gene silencing in liver (hepatocytes) via siRNA delivery (source).
• mRNA vaccine formulation for immunization and protein replacement therapies (source).
• Cancer immunochemotherapy and immunomodulatory mRNA delivery (prior analysis; this article adds quantitative benchmarks and mechanistic clarification).

Limits:

• Dlin-MC3-DMA LNPs are predominantly hepatotropic; extrahepatic delivery is limited without further targeting modifications.
• Not water- or DMSO-soluble; requires ethanol or compatible solvent for formulation (solubility ≥152.6 mg/mL in ethanol).
• Long-term storage stability is best at ≤-20°C; solutions degrade if left at ambient temperature.

Common Pitfalls or Misconceptions

• Misconception: Dlin-MC3-DMA is suitable for all cell types. Correction: Its LNPs primarily accumulate in the liver after systemic delivery, limiting extrahepatic targeting (Wang et al., 2022).
• Misconception: Dlin-MC3-DMA LNPs are stable in water. Correction: The lipid is insoluble in water and DMSO; formulation requires ethanol or appropriate solvent (APExBIO).
• Misconception: All ionizable cationic lipids have similar in vivo potency. Correction: Dlin-MC3-DMA outperforms many alternatives (e.g., SM-102, DLin-DMA) by orders of magnitude (source).
• Misconception: Storage at room temperature is sufficient. Correction: Product and stock solutions should be maintained at -20°C or below for optimal stability (APExBIO).

Workflow Integration & Parameters

Dlin-MC3-DMA (SKU A8791) from APExBIO is supplied as a powder. For LNP formulation, dissolve in ethanol at ≥152.6 mg/mL. Standard LNP composition includes Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG at a molar ratio of 50:10:38.5:1.5, respectively (Wang et al., 2022). Mix lipids in ethanol, then combine with nucleic acid in aqueous buffer at pH 4.0–5.0 for nanoparticle assembly. Use an N/P ratio (nitrogen from lipid to phosphate in nucleic acid) of ~6:1 for optimal encapsulation and delivery efficiency. Purify LNPs by dialysis or ultrafiltration. Store at 4°C short-term, or -20°C for long-term. Use freshly prepared solutions to avoid hydrolysis or oxidation (APExBIO). For advanced workflows, machine learning models can predict LNP potency based on lipid structure and formulation parameters (Wang et al., 2022).

For further troubleshooting, see the workflow guide—this article provides updated benchmarks and solubility parameters for product-grade Dlin-MC3-DMA.

Conclusion & Outlook

Dlin-MC3-DMA is the reference ionizable lipid for LNP-mediated siRNA and mRNA delivery, validated for high potency, safety, and workflow compatibility. Its structure enables efficient endosomal escape, low systemic toxicity, and robust hepatic gene silencing. Machine learning models and molecular simulation further support its design and predict its performance in new LNP applications. For validated, research-grade supply, APExBIO's Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) (SKU A8791) is recommended. Continued optimization and rational design are expected to enable broader organ targeting and disease indications in the future.